The communication of a secondary care diagnosis of autoimmune hepatitis to primary care practitioners:a population-based study by Varyani, Fumi et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The communication of a secondary care diagnosis of
autoimmune hepatitis to primary care practitioners
Citation for published version:
Varyani, F, Card, T, Kaye, P, Aithal, GP & West, J 2013, 'The communication of a secondary care diagnosis
of autoimmune hepatitis to primary care practitioners: a population-based study' BMC Health Services
Research, vol. 13, pp. 161. DOI: 10.1186/1472-6963-13-161
Digital Object Identifier (DOI):
10.1186/1472-6963-13-161
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
BMC Health Services Research
Publisher Rights Statement:
© 2013 Varyani et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Varyani et al. BMC Health Services Research 2013, 13:161
http://www.biomedcentral.com/1472-6963/13/161RESEARCH ARTICLE Open AccessThe communication of a secondary care
diagnosis of autoimmune hepatitis to primary
care practitioners: a population-based study
Fumi Varyani1*, Timothy Card1,2, Philip Kaye3, Guru P Aithal1 and Joe West2Abstract
Background: Autoimmune Hepatitis is a chronic liver disease which affects young people and can result in liver
failure leading to death or transplantation yet there is a lack of information on the incidence and prevalence of this
disease and its natural history in the UK. A means of obtaining this information is via the use of clinical databases
formed of electronic primary care records. How reliably the diagnosis is coded in such records is however
unknown. The aim of this study therefore was to assess the proportion of consultant hepatologist diagnoses of
Autoimmune Hepatitis which were accurately recorded in General Practice computerised records.
Methods: Our study population were patients with Autoimmune Hepatitis diagnosed by consultant hepatologists
in the Queens Medical Centre, Nottingham University Hospitals (UK) between 2004 and 2009. We wrote to the
general practitioners of these patients to obtain the percentage of patients who had a valid READ code specific for
Autoimmune Hepatitis.
Results: We examined the electronic records of 51 patients who had biopsy evidence and a possible diagnosis of
Autoimmune Hepatitis. Forty two of these patients had a confirmed clinical diagnosis of Autoimmune Hepatitis by
a consultant hepatologist: we contacted the General Practitioners of these patients obtaining a response rate of
90.5% (39/42 GPs). 37/39 of these GPs responded with coding information and 89% of these patients (33/37) used
Read code J638.00 (Autoimmune Hepatitis) to record a diagnosis.
Conclusions: The diagnosis of Autoimmune Hepatitis made by a Consultant Hepatologist is accurately
communicated to and electronically recorded by primary care in the UK. As a large proportion of cases of
Autoimmune Hepatitis are recorded in primary care, this minimises the risk of introducing selection bias and
therefore selecting cases using these data will be a valid method of conducting population based studies on
Autoimmune Hepatitis.Background
Autoimmune hepatitis (AIH) is a chronic liver disease
with an immune mediated aetiology. The disease is rare
with an annual incidence of 1.9/100000 [1] and has a bi-
modal age distribution with median age at diagnosis ap-
proximately 43 years [2]. It is an uncommon but
important disease due to the potential for decompensated
cirrhosis and the requirement of an orthotropic liver
transplant in otherwise young, healthy people. Recent data* Correspondence: fumi_varyani@hotmail.com
1Department of Gastroenterology, Queens Medical Centre, Nottingham
University Hospital NHS Trust, Derby Road, Nottingham NG7 2UH, United
Kingdom
Full list of author information is available at the end of the article
© 2013 Varyani et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfrom a non-transplant centre in the UK has estimated the
10 year survival to be 82% [3].
The clinical features of AIH are complicated and require
a strong clinical suspicion with contributory evidence such
as a suggestive liver biopsy, auto-antibodies (anti-nuclear
antibodies, anti-smooth muscle cell and anti-liver kidney
microsomal antibodies) or an elevated Immunoglobulin G
(IgG) titre. Liver biopsy should classically show active
interface hepatitis with lymphocytic and plasma-cell infil-
trates. There have been several scoring criteria formulated
for diagnosis which include the original, revised and sim-
plified [4] criteria by the International Autoimmune Hepa-
titis group. However, the consensus is that clinical
diagnosis is most important [1].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ease, it is difficult to obtain large cohorts of patients to
study. Previous studies have used multiple hospital data
collection methods, and the largest study so far has
obtained 473 patients with Autoimmune Hepatitis [2].
However, these methods are not without potential selec-
tion bias and considerable expense. The use of
population-based databases may provide an alternative
means of obtaining a large cohort of AIH patients. The
strengths of databases include prospective, systematic
collection of data including exposures, confounders and
outcome information. However, their limitations include
concerns about the validity of a diagnosis of Auto-
immune Hepatitis within the database. The UK General
Practice Research Database is one such population-
based database. It has over 5 million currently registered
patients [5] and it is therefore estimated would provide
between 1000–2500 unique patients for studies of the
epidemiology of Autoimmune Hepatitis. We have there-
fore aimed to validate the sensitivity of diagnosis of AIH
in electronic primary care data in order to assess its use-
fulness for studying AIH.Table 1 The simplified autoimmune hepatitis criteria [4]
Parameter Cutoff Score
ANA or SMA >=1:40 1
ANA or SMA >=1:80 2
or LKM >=1:40 2
SLA Positive 2
IgG > Upper normal limit 1
>1.1 Upper normal limit 2
Liver Histology Compatible with AIH 1
Typical of AIH 2
The score of each separate parameters are added to provide a simplified
scoring system for the diagnosis of autoimmune hepatitis. A score of 6 would
be classified as probable AIH, and a score of 7 or more would be definite AIH.
A maximum of 2 points will be achieved by addition of all auto-antibodies. For
the liver histology, interface hepatitis, lymphocytic/lymphoplamocytic plasma
cell infiltrates in portal tracts emperiolysis and hepatic rosette formation were
regarded as typical for the diagnosis of AIH. In order to be considered typical,
three features had to be present, in order to be classified as compatible,
chronic hepatitis with lymphocytic infiltration without all the features
considered to be typical were adequate [6]. Abbreviations: ANA (Anti-nuclear
autoantibodies), SMA (Smooth muscle autoantibody), LKM (Liver Kidney
Microsomal autoantibody) and SLA (Soluble Liver antigen), IgG
(Immunoglobulin G).Methods
Population
The study population were all patients within the catch-
ment area of Queens Medical Centre, Nottingham Uni-
versity Hospitals UK who were diagnosed by a
Consultant Hepatologist with Autoimmune Hepatitis
(AIH) between 2004 till 2009. We identified these pa-
tients from a list of liver biopsies discussed at a weekly
liver biopsy meeting held in the Nottingham University
Hospitals, Queens Medical Centre, the larger of the two
major hospitals providing Hepatology services to Not-
tingham, UK). In addition there were a small number of
biopsies of patients from nearby District General Hospi-
tals which were reviewed at this meeting.
Nottingham University Hospitals has an electronic sys-
tem for recording clinic letters and discharge informa-
tion (NOTIS), which is accessible along with their
laboratory, histopathology and microbiology results.
Where possible, we obtained these electronic records for
those patients with biopsy features of autoimmune hepa-
titis. We reviewed all patients who had a suggestion of
autoimmune hepatitis on their biopsies and who were
ever given a clinical label of Autoimmune Hepatitis.
Those patients who had available hospital records dem-
onstrating an initial diagnosis of AIH (by a Consultant
Hepatologist) and through the course of their clinical
encounter were shown not to have an alternative diagno-
sis became our cohort of patients with Autoimmune
Hepatitis. As the course of their disease progressed,
some of these patients received an alternative diagnosisor an additional diagnosis as part of an overlap syn-
drome. We maintained a record of these cases also.
Validation of clinical diagnosis
If full electronic records were available for the patient,
we performed a simplified autoimmune hepatitis score.
This score was created by the International Auto-
immune hepatitis group in 2008 [4]. In brief its compos-
ition is as follows: a maximum of two points are
allocated for auto-antibodies, one for an ANA or SMA
>=1:40; two for an ANA or SMA >>=1:80, a LKM
>=1:40 or SLA positive; IgG >1 times the upper limit of
normal (ULN) is allocated one point and >1.1 ULN two
points; liver histology that is consistent with auto-
immune hepatitis receives one point, and one that is typ-
ical of autoimmune hepatitis would receive two; finally
the absence of viral hepatitis gains two points. An over-
all score greater than 6 is classified as probable auto-
immune hepatitis, whilst a score greater than 7 is
definite autoimmune hepatitis (Table 1). In order to be
considered histologically typical three of the following
features must be present: interface hepatitis, lympho-
cytic/lymphoplasmocytic infiltrates in portal tracts and
extending into the lobule, emperiopolesis (active pene-
tration by one cell into and through a larger cell) and
hepatic rosette formation. A chronic hepatitis with
lymphocytic infiltration (without all the features consid-
ered to be typical) is considered compatible. As our
histopathology department does not regularly examine
biopsies for evidence of hepatic rosette formation or
emperiopolesis (typical features of autoimmune hepatitis
by simplified scoring criteria) we chose to score all our
Table 2 Demographic information
Age at diagnosis 48 (n=39)
Sex (% Female) 35/41 (85%)
IgG > ULN (%) 19/36 (53%)
SMA Positivity (%) 15/38 (40%)
ANA Positivity (%) 23/38 (61%)
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autoimmune hepatitis. A proportion of biopsies were
reviewed by Dr P Kaye (Consultant Histopathologist,
Queens Medical Centre, Nottingham University Hospi-
tals, UK) where elements of the histological classification
were unclear from the original report and a consensus
reached with Dr GP Aithal as to the ranking given.n=42 patients with AIH. Subsequent denominators for the results depend on
availability of results for patients. Abbreviations are as outlined in Table 1.Assessment of diagnoses coded in general practice for
the study population
General Practitioners in the UK use Read codes to code
diagnoses. AIH is coded specifically by the two Read
codes J63B.00 Autoimmune Hepatitis and J614111 Auto-
immune Chronic Active Hepatitis. It can be coded non-
specifically by numerous other codes.
We sent the General Practitioners (GPs) of all the pa-
tients we had defined as having AIH a letter asking them
if these patients had a code for autoimmune hepatitis in
their system and if so what code had been used. We also
asked how this diagnosis had been communicated to the
primary care team. A similar methodology has previ-
ously been used by our group for diverticular disease [6].
In the process of identifying patients with AIH, we
also identified a cohort of patients who initially receive a
diagnosis of AIH, but whose final diagnosis was differ-
ent. These patients were not scored with the simplified
autoimmune hepatitis score. However, letters were sent
to their general practitioners asking them if they had
READ codes for a range of liver diagnoses (including
autoimmune hepatitis, chronic hepatitis, primary biliary
cirrhosis and primary sclerosing cholangitis) to assess
the possibility of mislabelling them as autoimmune
hepatitis. We similarly wrote to those GP surgeries who
were caring for patients with any overlap syndrome i.e.
PBC/PSC, PBC/AIH or PSC/AIH overlap syndromes.
We carried out this work as an audit registered within
the NUH NHS Trust (Audit ID 1582).Figure 1 Flow chart of patients in study and the availability of
their electronic records for a simplified AIH score. We had 51
patients available to study, 2 patients were from another district, and
we had no information available about them. 7 patients were
subsequently found to have other diagnoses. 42 out of 51 notes
examined had a consistent diagnosis of autoimmune hepatitis. Of
these, we only had full electronic information available for 79% of
these patients.Results
Study population identified
We identified 51 biopsy reports between 2004 and 2009
in which the possibility of AIH was raised.
After assessment a total of 42 patients were classified
consistently as having AIH in secondary care. We were
able to obtain demographic and immunological informa-
tion on the majority of these patients. The approximate
age at diagnosis was 48 years, 85% of patients with auto-
immune hepatitis were female. 53% of patients with Im-
munoglobulin G (IgG) levels available had an IgG level
greater than the upper limit of normal, 40% of patients
with autoantibody information available were Smooth
muscle autoantibody (SMA) positive and and 61% were
Anti-nuclear autoantibody (ANA) positive (Table 2).Of these 42 patients, 33 patients had adequate elec-
tronic records available, enabling us to complete a sim-
plified AIH score (Table 1). Of the remaining 9 patients,
seven had other diagnoses or an overlap syndrome and
two had no electronic notes available because their biop-
sies came from another region as demonstrated in
Figure 1.Simplified autoimmune hepatitis score
Using this criteria to categorise biopsies we found 28/33
patients had a score which predicted probable or definite
AIH (85%), (Table 3).Overall response rate
We sent 49 letters to General Practitioners and received
46 replies (an overall response rate of 95%). We were
unable to send 2 letters because GP address information
was not available to us, this was primarily because these
biopsies were sent to the liver meeting to provide a sec-
ond opinion, and then sent back to the local trust. Nei-
ther the biopsies nor the demographic information
about the patients were retained beyond the meeting for
these two biopsies.
Table 3 Scores obtained by the simplified autoimmune
hepatitis criteria
Autoimmune hepatitis
scoring criteria
Number of patients with
a particular score
>=7 (Definite) 16
6 (Probable) 12
5 2
4 3
3 0
2 0
1 0
N=33 AIH patients with all available data to calculate a score. We found 28/33
(85%) had a score giving them definite or probable autoimmune hepatitis.
Table 5 Patients found to have another diagnosis (or an
overlap syndrome)
Patient Final consultant
diagnosis
Read code in general practice
1 Ductopenia J638.00 Autoimmune Hepatitis
2 PSC/AIH overlap
syndrome
J638.00 Autoimmune Hepatitis
J661700 Primary Sclerosis Cholangitis
3 PBC/PSC overlap
syndrome
J616000 Primary Biliary Cirrhosis
J614.00 Chronic Hepatitis
Free text in clinic letter ?sclerosing cholangitis
4 PBC J616000 Primary Biliary Cirrhosis
5 PBC J616000 Primary Biliary Cirrhosis
J638.00 Autoimmune Hepatitis
6 PBC/AIH overlap
syndrome
No letter received from GP
7 PSC J661700 Primary Sclerosing Cholangitis
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In the study of communication of a secondary care diag-
nosis of autoimmune hepatitis, we were able to contact
the GPs of all 42 patients of our original cohort of auto-
immune hepatitis. The overall response rate was 39/42
(93%). 37/39 of the practices responded with coding in-
formation, and 33/37 (89%) used Read code 638.00
Autoimmune Hepatitis. None of the practices used the
alternative Read code J14111 Autoimmune Chronic Ac-
tive Hepatitis. Three practices (8%) used non-specific
read codes J614100 Chronic Active Hepatitis, and
J614.00 for Chronic Hepatitis and one practice used free
text to record autoimmune hepatitis (Table 4).
Other diagnoses and overlap syndromes
Three patients had an overlap syndrome and four even-
tually were found to have another diagnosis (Table 5).
We received responses from 6/7 of these GPs (86%).
71% of the GP letters available to us were coded accur-
ately. As there are no Read codes for overlap syndromes
in General Practice coding systems, GPs would docu-
ment two separate codes for each of the components of
the overlap syndrome (Table 5).
Discussion
More than 300 studies have been performed to assess
the positive predictive value of the coding of diseases for
the presence of the coded diagnosis. These have inTable 4 Responses obtained from the practices
READ code N
J638.00 Autoimmune Hepatitis 33/37 (89%)
J614100 Chronic Active Hepatitis 1
J614.00 Chronic Hepatitis 2
Free text box: Autoimmune hepatitis 1
39 practices, out of 42 we wrote to (response rate 93%) and coding method
used to document Autoimmune Hepatitis in General Practice. We had 37
responses with coding information available, 2 had left the practice or no
information was available.general found high positive predictive values in the order
of 90% [7,8]. It is likely that the same will be true for
Autoimmune Hepatitis, but that is not what this study
has examined. We in contrast have examined the sensi-
tivity of the coded diagnosis of a chronic disease for its
presence, and this to our knowledge has very rarely been
done before [9].
We assessed the validity of the coding of AIH using a
cohort of 42 patients with AIH and 7 patients with other
diagnoses or an overlap syndrome whose biopsies were
reviewed at the liver biopsy meeting at the Queens Med-
ical Centre, Nottingham, UK, between 2004 and 2009.
The diagnosis of AIH is complicated, as essentially there is
no single pathognomonic feature [1] and the clinical con-
text is of the utmost importance. Despite there being vali-
dated scoring criteria, the consensus of recent British
Society of Gastroenterology guidelines on AIH is that this
diagnosis requires considerable “clinical expertise” [1] and
scoring should be used as an adjunct. We chose to use a
consultant diagnosis of autoimmune hepatitis as our gold
standard as had Yeoman [10]. We had 42 patients avail-
able to us who had a clinical diagnosis of AIH as con-
firmed by the managing hepatologist, for whom we
requested coding information from GPs. We received 39
responses, 37 of the patients had coded or free text infor-
mation available for the diagnosis of autoimmune hepa-
titis. Two additional practices wrote back to us to state
the patient had left the practice or that they patient was
deceased and they no longer held their electronic or paper
records (Table 4). Of the 37 GP practices which had infor-
mation available on the electronic recording of patient
data, 89% used a specific READ code for Autoimmune
Hepatitis (J638.00 Autoimmune Hepatitis). Others had
used non-specific codes which may be interpreted as other
forms of liver disease or used free text (Table 4).
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diagnosis of Autoimmune Hepatitis for the detection of
this condition in General Practice is 89% i.e. 89% of all
people diagnosed with Autoimmune Hepatitis in hos-
pital get a specific code in electronic primary care re-
cords for Autoimmune Hepatitis. This high sensitivity
ensures that electronic records are unlikely greatly to
underreport the incidence and prevalence of AIH and
thus such records are suitable for studying the epidemi-
ology of AIH in databases such as the General Practice
Research Database, QResearch or the Health Improve-
ment Network in the United Kingdom. Mediplus is a
general practice database used in France, Austria and
Germany; Holland uses PHARMO, IPCI and PALGO. In
addition there are hospital based databases in England,
Spain, Sweden Canada, Australia, Asia (China, Hong
Kong, Japan, South Korea, Taiwan and Singapore), Latin
America (Brazil, Argentina, Mexico, Venezuela, Peru,
Chile). Evidence exists that data from the UKGPRD cor-
relates with other databases in Europe e.g. fracture risk
in coeliac disease was found to be increased to the same
extent in both the UK GPRD [11] and in the Swedish
National Inpatient Register [12] There are also Danish
Registries which have been used to look at liver diseases
[13].
Seven of the initial fifty patients were subsequently
found to have other diagnoses, or overlap syndromes.
We wrote to their general practitioners to assess the
possibility of a miscoded diagnosis of AIH. If we were
considering performing population-based studies, we
would be able to exclude most of the overlap and
misdiagnosed patients by excluding any person with a
code for another form of liver disease as well as auto-
immune hepatitis. 71% of these overlap syndromes or
those with subsequent diagnoses were accurately coded.
Limitations
A limitation of this study in the assessment of validity is
that it assessed sensitivity of AIH alone. Other measures
of diagnostic accuracy or utility include positive predictive
value, specificity and negative predictive value. We believe
the positive predictive value of AIH to be high in elec-
tronic primary care data because this has been shown to
be the case in other gastrointestinal diseases such as
Coeliac Disease, IBD, Cirrhosis [14] all of which require a
similar diagnostic process to AIH including assessment in
secondary care and a combination of clinical judgement,
laboratory and histological results. Nonetheless further
work looking at the positive predictive value of this diag-
nosis in the GPRD, validating against Hospital Episode
Statistics records and/or the clinic letters/discharge infor-
mation available to the General Practitioners would en-
hance our confidence in the value of these data. We
believe the negative predictive value of a disease such asAIH which has an incidence of approximately 1.9/100 000
would be high simply because it is so uncommon. Other
limitations include the lack of data on a therapeutic re-
sponse, however, as this was a retrospective study there
was insufficient information available to come to a valid
conclusion about therapy.
All the patients were sourced via the liver biopsy meet-
ing in Nottingham University Hospitals. In Nottingham it
is unit policy to biopsy all patients in whom a diagnosis of
AIH is made in view of the potentially lifelong therapy
which is being embarked upon. Hence in Nottingham only
patients who decline a biopsy will not be biopsied. The
method chosen to obtain patients for the audit was
recommended by the departmental hepatologists as it
would be least likely to miss any cases. When compared
to a non-transplant centre’s experience of autoimmune
hepatitis in Sheffield, only 16 out our 245 cases did not
have an initial biopsy, and eventually 7 underwent a bi-
opsy [3].Conclusions
Use of electronic primary care data for studying the epi-
demiology of Autoimmune Hepatitis will be an efficient
means of studying this disease, enabling access to large
population-based cohorts in order to answer some of
the important questions of the contemporary natural
history of this disease. Our results suggest, we will
through such work be able to precisely quantify the inci-
dence and prevalence of AIH without fear of grossly
underestimating the disease as the sensitivity of the re-
cording is so good. Equally, studies of aetiology and con-
sequence should be able to provide much needed
insights into this condition. Further work into the posi-
tive predictive value of this disease in electronic data is
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